Effects of MCP-1 inhibition by bindarit therapy in a rat model of polycystic kidney disease

Nephron

Volumn 129, Issue 1, 2015, Pages 52-61

  Zoja, Carlamaria ^a   Corna, Daniela ^a   Locatelli, Monica ^a   Rottoli, Daniela ^a   Pezzotta, Anna ^a   Morigi, Marina ^a   Zanchi, Cristina ^a   Buelli, Simona ^a   Guglielmotti, Angelo ^b   Perico, Norberto ^a   Remuzzi, Andrea ^a   Remuzzi, Giuseppe ^a,c  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b Università Politecnica delle Marche ACRAF Gruppo Angelini   (Italy)

^c Azienda Ospedaliera Papa Giovanni XXIII   (Italy)

Author keywords

Bindarit; Interstitial inflammation; MCP 1; PCK rat; Podocyte; Polycystic kidney disease; Proteinuria

Indexed keywords

ALBUMIN; BINDARIT; CREATININE; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; NEPHRIN; CCL2 PROTEIN, MOUSE; INDAZOLE DERIVATIVE; PROPIONIC ACID DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL MIGRATION; CELL STRUCTURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; EPITHELIUM CELL; GLOMERULUS BASEMENT MEMBRANE; IN VITRO STUDY; INFLAMMATORY CELL; KIDNEY INTERSTITIUM; KIDNEY POLYCYSTIC DISEASE; LIVER CYST; MACROPHAGE; MALE; MONOCYTE; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RAT; TRANSMISSION ELECTRON MICROSCOPY; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; DISEASE MODEL; DRUG EFFECTS; GENETICS; METABOLISM; MUTANT RAT STRAIN; PATHOLOGY; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; SPRAGUE DAWLEY RAT;

ANIMALS; CHEMOKINE CCL2; DISEASE MODELS, ANIMAL; IN VITRO TECHNIQUES; INDAZOLES; MACROPHAGES; MALE; MONOCYTES; PODOCYTES; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; PROPIONATES; PROTEINURIA; RATS; RATS, MUTANT STRAINS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER;

EID: 84940950180     PISSN: 16608151     EISSN: 22353186     Source Type: Journal    
DOI: 10.1159/000369149     Document Type: Article

References (25)

1. Harris PC, Torres VE: Polycystic kidney disease. Annu Rev Med 2009; 60:321-337.
2. Grantham JJ, Mulamalla S, Swenson-Fields KI: Why kidneys fail in autosomal dominant polycystic kidney disease. Nat Rev Nephrol 2011; 7:556-566.
3. Torres VE, Harris PC: Strategies targeting cAMP signaling in the treatment of polycystic kidney disease. J Am Soc Nephrol 2014; 25:18-32.
4. Ruggenenti P, Remuzzi A, Ondei P., Fasolini G, Antiga L, Ene-Iordache B, Remuzzi G., Epstein FH: Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney Int 2005; 68:206-216.
5. Torres VE, Chapman AB, Devuyst O, Gansevoort R.T., Grantham JJ, Higashihara E, Perrone RD, Krasa H.B., Ouyang J., Czerwiec FS: Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2012; 367:2407-2418.
6. Caroli A, Perico N, Perna A., Antiga L, Brambilla P, Pisani A, Visciano B., Imbriaco M, Messa P, Cerutti R, Dugo M, Cancian L, Buongiorno E, De Pascalis A, Gaspari F, Carrara F, Rubis N, Prandini S, Remuzzi A, Remuzzi G, Ruggenenti P: Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial. Lancet 2013; 382: 1485-1495.
7. Ta MH, Harris DC, Rangan GK: Role of interstitial inflammation in the pathogenesis of polycystic kidney disease. Nephrology (Carlton) 2013; 18:317-330.
8. Zeier M, Fehrenbach P, Geberth S., Mohring K, Waldherr R, Ritz E: Renal histology in polycystic kidney disease with incipient and advanced renal failure. Kidney Int 1992; 42: 1259-1265.
9. Karihaloo A, Koraishy F, Huen S.C., Lee Y., Merrick D, Caplan MJ, Somlo S, Cantley LG: Macrophages promote cyst growth in polycystic kidney disease. J Am Soc Nephrol 2011; 22:1809-1814.
10. Swenson-Fields KI, Vivian CJ, Salah S.M., Peda JD, Davis BM, van Rooijen N, Wallace DP, Fields TA: Macrophages promote polycystic kidney disease progression. Kidney Int 2013; 83: 855-864.
11. Cowley BD Jr, Ricardo SD, Nagao S, Diamond JR: Increased renal expression of monocyte chemoattractant protein-1 and os-teopontin in ADPKD in rats. Kidney Int 2001; 60:2087-2096.
12. Zheng D, Wolfe M, Cowley BD Jr, Wallace DP, Yamaguchi T, Grantham JJ: Urinary excretion of monocyte chemoattractant protein-1 in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2003; 14: 2588-2595.
13. Mirolo M, Fabbri M, Sironi M., Vecchi A, Guglielmotti A, Mangano G., Biondi G, Locati M, Mantovani A: Impact of the anti-inflammatory agent bindarit on the chemokin-ome: selective inhibition of the monocyte chemotactic proteins. Eur Cytokine Netw 2008; 19:119-122.
14. Lager DJ, Qian Q, Bengal R.J., Ishibashi M., Torres VE: The pck rat: a new model that resembles human autosomal dominant polycystic kidney and liver disease. Kidney Int 2001; 59:126-136.
15. Zoja C, Cattaneo S, Fiordaliso F., Lionetti V, Zambelli V, Salio M., Corna D, Pagani C, Rottoli D, Bisighini C, Remuzzi G, Benigni A: Distinct cardiac and renal effects of ETA receptor antagonist and ACE inhibitor in experimental type 2 diabetes. Am J Physiol Renal Physiol 2011; 301:F1114-F1123.
16. Morigi M, Buelli S, Angioletti S., Zanchi C, Longaretti L, Zoja C., Galbusera M, Gastoldi S, Mundel P Remuzzi G, Benigni A: In response to protein load podocytes reorganize cytoskeleton and modulate endothelin-1 gene: implication for permselective dysfunction of chronic nephropathies. Am J Pathol 2005; 166:1309-1320.
17. Mora E, Guglielmotti A, Biondi G., Sassone-Corsi P: Bindarit: an anti-inflammatory small molecule that modulates the NFκB pathway. Cell Cycle 2012; 11:159-169.
18. Guglielmotti A, D'Onofrio E, Coletta I, Aquilini L., Milanese C, Pinza M: Amelioration of rat adjuvant arthritis by therapeutic treatment with bindarit, an inhibitor of MCP-1 and TNF-alpha production. Inflamm Res 2002; 51:252-258.
19. Zoja C, Corna D, Benedetti G., Morigi M, Donadelli R, Guglielmotti A., Pinza M, Bertani T, Remuzzi G: Bindarit retards renal disease and prolongs survival in murine lupus autoimmune disease. Kidney Int 1998; 53:726-734.
20. Ble A, Mosca M, Di Loreto G, Guglielmotti A, Biondi G., Bombardieri S, Remuzzi G, Ruggenenti P: Antiproteinuric effect of chemokine C-C motif ligand 2 inhibition in subjects with acute proliferative lupus nephritis. Am J Nephrol 2011; 34:367-372.
21. Mrug M, Zhou J, Woo Y., Cui X, Szalai AJ, Novak J, Churchill G.A., Guay-Woodford LM: Overexpression of innate immune response genes in a model of recessive polycystic kidney disease. Kidney Int 2008; 73:63-76.
22. Chapman AB, Johnson AM, Gabow P.A., Schrier RW: Overt proteinuria and microalbuminuria in autosomal-dominant polycystic kidney disease. J Am Soc Nephrol 1994; 5:1349-1354.
23. Chapman AB, Guay-Woodford LM, Grantham J.J., Torres VE, Bae KT, Baumgarten DA, Kenney P.J., King BF Jr, Glockner JF, Wetzel LH, Brummer ME, O'Neill WC, Robbin ML, Bennett WM, Klahr S, Hirschman GH, Kimmel PL, Thompson PA, Miller JP: Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort. Kidney Int 2003; 64:1035-1045.
24. Lee EY, Chung CH, Khoury C.C., Yeo TK, Pyagay PE, Wang A, Chen S: The monocyte chemoattractant protein-1/CCR2 loop, inducible by TGF-beta, increases podocyte motility and albumin permeability. Am J Physiol Renal Physiol 2009; 297:F85-F94.
25. Tarabra E, Giunti S, Barutta F., Salvidio G, Burt D, Deferrari G., Gambino R, Vergola D, Pinach S, Perin PC, Camussi G, Gruden G: Effect of the monocyte chemoattractant protein-1/CC chemokine receptor 2 system on nephrin expression in streptozotocin-treated mice and human cultured podocytes. Diabetes 2009; 58:2109-2118.